Overview
Ambry Genetics provides genetic testing services for hereditary cancer, heart conditions, neurological disorders, and rare diseases. Its tests analyze DNA and RNA to generate actionable results that help healthcare professionals make informed patient care decisions. The company combines advanced molecular analysis with a patient-centered approach, supported by partnerships with researchers and institutions, to expand access through insurer coverage and financial assistance. Unlike some competitors, Ambry emphasizes long-standing clinical collaboration, broad test menus, and practical patient access initiatives in order to advance precision medicine. The company's goal is to improve personalized healthcare by enabling earlier detection, prevention, and targeted treatment for individuals at risk of inherited diseases.
Work here?Claim your company
Simplify's take
What believers are saying
- Ambry announced its one-millionth DNA/RNA test on February 2, 2026.
- A 2026 Genetics in Medicine Open study validated ExomeReveal RNA for VUS resolution.
- Tempus projected 2025 consolidated revenue near $1.25 billion after closing Ambry.
What critics are saying
- Tempus paid $375 million cash and $225 million shares on February 3, 2025.
- Payer coverage cuts crush hereditary-testing margins when insurers restrict RNA and WGS reimbursement.
- A Tempus platform pivot commoditizes Ambry's hereditary menu and erodes its distinct clinical brand.
What makes Ambry Genetics unique
- Tempus owns Ambry since February 3, 2025, pairing hereditary testing with oncology data.
- GenomeNext launched October 13, 2026, combining WGS, RNA analysis, and proactive reanalysis.
- Ambry’s CARE Program embeds genetic-risk screening inside EHR workflows for clinicians.
Help us improve and share your feedback! Did you find this helpful?